Home  /  Resource Library  /  Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy

Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy

ASCO 2020: Results of a retrospective study examining outcomes of elderly patients with relapsed DLBCL treated with CAR T therapy axicabtagene ciloleucel or tisagenlecleucel.